Cotranscriptional exon skipping in the genotoxic stress response

Nature Structural and Molecular Biology

Volumn 17, Issue 11, 2010, Pages 1358-1366

  Dutertre, Martin ^a   Sanchez, Gabriel ^a   De Cian, Marie Cécile ^a,b   Barbier, Jérôme ^a   Dardenne, Etienne ^a   Gratadou, Lise ^a   Dujardin, Gwendal ^a   Le Jossic Corcos, Catherine ^a   Corcos, Laurent ^a   Auboeuf, Didier ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; REGULATOR PROTEIN; RNA POLYMERASE II; TRANSCRIPTOME; UBIQUITIN PROTEIN LIGASE; Y BOX BINDING PROTEIN 1;

ARTICLE; EWING SARCOMA; EXON; GENOTOXICITY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; RNA TRANSCRIPTION; SPLICEOSOME; STRESS;

CAMPTOTHECIN; CELL LINE; DNA DAMAGE; DNA POLYMERASE II; DNA-BINDING PROTEINS; EXONS; GENE EXPRESSION REGULATION; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; RNA SPLICING; RNA-BINDING PROTEIN EWS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78549288104     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1912     Document Type: Article

References (61)

1. Zorio, D.A. & Bentley, D.L. The link between mRNA processing and transcription: communication works both ways. Exp. Cell Res. 296, 91-97 (2004).
2. Listerman, I., Sapra, A.K. & Neugebauer, K.M. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat. Struct. Mol. Biol. 13, 815-822 (2006).
3. Wetterberg, I., Bauren, G. & Wieslander, L. The intranuclear site of excision of each intron in Balbiani ring 3 pre-mRNA is infuenced by the time remaining to transcription termination and different excision effciencies for the various introns. RNA 2, 641-651 (1996).
4. Bittencourt, D. et al. Cotranscriptional splicing potentiates the mRNA production from a subset of estradiol-stimulated genes. Mol. Cell. Biol. 28, 5811-5824 (2008).
5. Ghosh, S. & Garcia-Blanco, M.A. Coupled in vitro synthesis and splicing of RNA polymerase II transcripts. RNA 6, 1325-1334 (2000).
6. Das, R. et al. Functional coupling of RNAP II transcription to spliceosome assembly. Genes Dev. 20, 1100-1109 (2006).
7. Stamm, S. et al. Function of alternative splicing. Gene 344, 1-20 (2005).
8. de la Mata, M. et al. A slow RNA polymerase II affects alternative splicing in vivo. Mol. Cell 12, 525-532 (2003)
9. Muñoz, M.J. et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 137, 708-720 (2009).
10. Auboeuf, D. et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol. Cell. Biol. 24, 442-453 (2004).
11. Masuhiro, Y. et al. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc. Natl. Acad. Sci. USA 102, 8126-8131 (2005)
12. Ljungman, M. & Hanawalt, P.C. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 17, 31-35 (1996).
13. Collins, I., Weber, A. & Levens, D. Transcriptional consequences of topoisomerase inhibition. Mol. Cell. Biol. 21, 8437-8451 (2001).
14. Jung, Y. & Lippard, S.J. RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase. J. Biol. Chem. 281, 1361-1370 (2006).
15. Ljungman, M. & Paulsen, M.T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodifed at Ser15 and Lys382. Mol. Pharmacol. 60, 785-789 (2001).
16. Ljungman, M. & Lane, D.P. Transcription - guarding the genome by sensing DNA damage. Nat. Rev. Cancer 4, 727-737 (2004)
17. Meek, D.W. The p53 response to DNA damage. DNA Repair (Amst.) 3, 1049-1056 (2004).
18. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y. & Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23, 2584-2592 (1995).
19. Wu, X., Bayle, J.H., Olson, D. & Levine, A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
20. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
21. Matsumoto, R. et al. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58, 609-613 (1998).
22. Bartel, F., Taubert, H. & Harris, L.C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2, 9-15 (2002).
23. Sigalas, I., Calvert, A.H., Anderson, J.J., Neal, D.E. & Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 2, 912-917 (1996).
24. Evans, S.C. et al. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20, 4041-4049 (2001).
25. Chandler, D.S., Singh, R.K., Caldwell, L.C., Bitler, J.L. & Lozano, G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 66, 9502-9508 (2006).
26. Dias, C.S., Liu, Y., Yau, A., Westrick, L. & Evans, S.C. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res. 66, 9467-9473 (2006).
27. Pochampally, R. et al. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17, 2629-2636 (1998).
28. Rigo, F. & Martinson, H.G. Functional coupling of last-intron splicing and 3'-end processing to transcription in vitro: the poly(A) signal couples to splicing before committing to cleavage. Mol. Cell. Biol. 28, 849-862 (2008).
29. Kornblihtt, A.R. Promoter usage and alternative splicing. Curr. Opin. Cell Biol. 17, 262-268 (2005).
30. Rossi, F. et al. Specifc phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381, 80-82 (1996).
31. Bertolotti, A. et al. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol. Cell. Biol. 18, 1489-1497 (1998).
32. Yang, L., Chansky, H.A. & Hickstein, D.D. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 275, 37612-37618 (2000).
33. Chansky, H.A., Hu, M., Hickstein, D.D. & Yang, L. Oncogenic TLS/ERG and EWS/ Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61, 3586-3590 (2001).
34. Petermann, R. et al. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17, 603-610 (1998).
35. Liang, H., Atkins, H., Abdel-Fattah, R., Jones, S.N. & Lunec, J. Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 338, 217-223 (2004).
36. Brand, M. et al. UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation. EMBO J. 20, 3187-3196 (2001).
37. Martinez, E. et al. Human staga complex is a chromatin-acetylating transcription coactivator that interacts with pre-mrna splicing and dna damage-binding factors in vivo. Mol. Cell. Biol. 21, 6782-6795 (2001).
38. Cavellán, E., Asp, P., Percipalle, P. & Farrants, A.K. The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription. J. Biol. Chem. 281, 16264-16271 (2006).
39. Clark, T.A. et al. Discovery of tissue-specifc exons using comprehensive human exon microarrays. Genome Biol. 8, R64 (2007).
40. Dutertre, M. et al. Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res. 70, 896-905 (2010).
41. Solier, S. et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol. Cancer Res. 2, 53-61 (2004).
42. Barbier, J. et al. Regulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways. Mol. Cell. Biol. 27, 7315-7333 (2007).
43. Marengo, M.S. & Wassarman, D.A.A. DNA damage signal activates and derepresses exon inclusion in Drosophila TAF1 alternative splicing. RNA 14, 1681-1695 (2008).
44. Sanchez, G. et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc. Natl. Acad. Sci. USA 105, 6004-6009 (2008)
45. Law, W.J., Cann, K.L. & Hicks, G.G. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief. Funct. Genomic Proteomic 5, 8-14 (2006)
46. Stickeler, E. et al. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 20, 3821-3830 (2001).
47. Hartmuth, K. et al. Protein composition of human prespliceosomes isolated by a tobramycin affnity-selection method. Proc. Natl. Acad. Sci. USA 99, 16719-16724 (2002)
48. Deckert, J. et al. Protein composition and electron microscopy structure of affnity-purifed human spliceosomal B complexes isolated under physiological conditions. Mol. Cell. Biol. 26, 5528-5543 (2006).
49. Allemand, E., Hastings, M.L., Murray, M.V., Myers, M.P. & Krainer, A.R. Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acid-binding protein YB-1. Nat. Struct. Mol. Biol. 14, 630-638 (2007).
50. Solier, S. et al. Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res. published online 3 September 2010, doi:10.1158/0008-5472. CAN-10-2491.
51. Pagani, F., Stuani, C., Zuccato, E., Kornblihtt, A.R. & Baralle, F.E. Promoter architecture modulates CFTR exon 9 skipping. J. Biol. Chem. 278, 1511-1517 (2003).
52. Pleiss, J.A., Whitworth, G.B., Bergkessel, M. & Guthrie, C. Rapid, transcript-specifc changes in splicing in response to environmental stress. Mol. Cell 27, 928-937 (2007).
53. Zhang, N. et al. The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J. Biol. Chem. 280, 40559-40567 (2005).
54. Singh, R.K., Tapia-Santos, A., Bebee, T.W. & Chandler, D.S. Conserved sequences in the fnal intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp. Cell Res. 315, 3419-3432 (2009).
55. Tanackovic, G. & Kramer, A. Human splicing factor SF3a, but not SF1, is essential for pre-mRNA splicing in vivo. Mol. Biol. Cell 16, 1366-1377 (2005)
56. Hastings, M.L., Allemand, E., Duelli, D.M., Myers, M.P. & Krainer, A.R. Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF65. PLoS ONE 2, e538 (2007).
57. Pacheco, T.R., Coelho, M.B., Desterro, J.M., Mollet, I. & Carmo-Fonseca, M. In vivo requirement of the small subunit of U2AF for recognition of a weak 3′ splice site. Mol. Cell. Biol. 26, 8183-8190 (2006).
58. Stommel, J.M. & Wahl, G.M. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4, 411-417 (2005).
59. Bargou, R.C. et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3, 447-450 (1997).
60. Shibahara, K. et al. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci. 95, 348-353 (2004).
61. De La Grange, P., Dutertre, M., Correa, M. & Auboeuf, D. A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants. BMC Bioinformatics 8, 180 (2007).